Roche halts Phase I trial
Roche has halted a trial of MAXY-alpha, also known as R7025, due to an unanticipated reduction of the pharmacodynamic and pharmacokinetic effects in patients who received the drug. Roche and development partner Maxygen are conducting Phase I trials of R7025 for Hepatitis C and Hepatitis B.
"We don't yet know how this will impact the future timing or advancement of the program. Roche has now started additional work to assess the meaning and significance of these results. We will provide an update once all relevant information is collected and evaluated," said Russell Howard, Maxygen's CEO. Back in March Roche opted out of another co-development deal with Maxygen for acute bleeding indications.
- see this release from Maxygen
Be the first to comment
More stories about Hepatitis C hepatitis B Roche Phase I Deals Maxygen R7025 MAXY-alpha Drug Development
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


